Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application. Researchers have developed an artificial intelligence (AI) model that can predict which scientific discoveries are more likely to translate to the clinic. The study was conducted by researchers from the Office of Portfolio Analysis (OPA), part of the US National Institutes of Health (NIH). The team say that their aim is to decrease the long interval between scientific discovery and clinical application. The new process determines the likelihood that a research article will be cited by a future clinical trial or guideline.
Like almost any field in the healthcare industry pharma wants to get in on the latest technology trends. Recently big pharma has been looking to artificial intelligence as another tool to help facilitate drug research and help the company progress. At the World Medical Innovation Forum in Boston on April 24, a panel of pharma leaders discussed the future of AI in the industry. "It's quite top of mind for us at Novartis as we are reimagining life science companies like ours as medicines companies powered by data and digital and also because the radical advances, perhaps driven by consumer applications of this critical vector of computer science, have overt, immediate, and profound downstream relevance," Dr. Jay Bradner, president of Novartis Institutes for Biomedical Research, said at Tuesday's event. That doesn't mean companies are ready to replace their researchers with robots anytime soon.
BenevolentTech CEO Pesenti: "What the company is doing here is not just the research but putting the drugs through the clinical trials ourselves." Pharmaceutical companies expend a lot of effort and millions of dollars developing new drugs -- and not the least of their problems is the amount of time spent researching potential advances that turn out to be a blind alley. A UK-based company believes that by the creative use of artificial intelligence, it can speed up that process by a factor of 10. BenevolentAI is using artificial intelligence tools to help it wade through millions of pages of drug research, analyse them, and come up with the most promising areas for research. The company recently appointed Jérôme Pesenti as CEO of its technology division, BenevolentTech.
A drug molecule "invented" by artificial intelligence (AI) will be used in human trials in a world first for machine learning in medicine. It was created by British start-up Exscientia and Japanese pharmaceutical firm Sumitomo Dainippon Pharma. The drug will be used to treat patients who have obsessive-compulsive disorder (OCD). Typically, drug development takes about five years to get to trial, but the AI drug took just 12 months. Exscienta chief executive Prof Andrew Hopkins described it as a "key milestone in drug discovery".
BenevolentAI is a London start-up that specializes in artificial intelligence (AI); its BenevolentBio division, formerly Stratified Medical, applies AI to human health and biotech. Its baby is a technology that could speed up late-stage development of drugs and provide richer clinical data. Now, it will test it using clinical stage drug candidates licensed from Janssen. Although there are no details on the particulars of the agreement, BenevolentAI is confident that it can accelerate clinical development and begin Phase IIb trials in mid-2017. If everything works out well, the company will have exclusive rights to develop, manufacture and commercialize these candidates.